Autoreactive T cell clones of MHC class II specificities are produced during responses against foreign antigens in man.A F Tilkin, Joshua Levy, H Bétuel et al.|The Journal of Immunology|1987Cited by 47
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I. Silverberg, Jonathan Zalevsky, David Rosmarin et al.|Nature Communications|2024Cited by 37
Efficacy and safety of the regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin (REZPEG) in the treatment of inflammatory skin diseases including atopic dermatitisJonathan Zalevsky, Brian L. Kotzin, Jonathan I. Silverberg et al.|Research Square|2024Cited by 0